Company profile ANNX

Annexon Inc
our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).
Quarter analysis & expected interest

There is not enough data for Annexon, Inc. to provide analysis

Correlation between past revenue and Annexon, Inc. search interest

There is not enough data for Annexon, Inc. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annexon, Inc. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annexon, Inc. therapeutics to provide analysis

Correlation between past revenue and Annexon, Inc. therapeutics search interest

There is not enough data for Annexon, Inc. therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annexon, Inc. therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANX005 clinical trials to provide analysis

Correlation between past revenue and ANX005 clinical trials search interest

There is not enough data for ANX005 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANX005 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANX009 lupus nephritis to provide analysis

Correlation between past revenue and ANX009 lupus nephritis search interest

There is not enough data for ANX009 lupus nephritis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANX009 lupus nephritis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANX007 geographic atrophy to provide analysis

Correlation between past revenue and ANX007 geographic atrophy search interest

There is not enough data for ANX007 geographic atrophy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANX007 geographic atrophy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANX105 neurodegenerative diseases to provide analysis

Correlation between past revenue and ANX105 neurodegenerative diseases search interest

There is not enough data for ANX105 neurodegenerative diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANX105 neurodegenerative diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANX1502 autoimmune indications to provide analysis

Correlation between past revenue and ANX1502 autoimmune indications search interest

There is not enough data for ANX1502 autoimmune indications to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANX1502 autoimmune indications to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annexon, Inc. stock to provide analysis

Correlation between past revenue and Annexon, Inc. stock search interest

There is not enough data for Annexon, Inc. stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annexon, Inc. stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annexon, Inc. contact information to provide analysis

Correlation between past revenue and Annexon, Inc. contact information search interest

There is not enough data for Annexon, Inc. contact information to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annexon, Inc. contact information to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annexon, Inc. careers to provide analysis

Correlation between past revenue and Annexon, Inc. careers search interest

There is not enough data for Annexon, Inc. careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annexon, Inc. careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ANNX
Earnings date: 2024-03-04 After close
Company name: Annexon Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-19T11:06:14.668817948Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25

2026-10-16T14:34:37-07:00

GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-09-30T17:46:53.870652132Z

Analyst Upgrades
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15

2026-09-16T13:05:00-07:00

GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-09-09T08:45:00-04:00

Earnings Call Transcripts
WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ANNEXON INC

2026-09-09T08:45:00-04:00

Earnings Call Transcripts
WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ANNEXON INC

2026-09-02T05:00:00-07:00

GlobeNewswire
Annexon to Participate in Upcoming September Investor Conferences

2026-09-01T18:34:22.106342386Z

Analyst Upgrades
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14

2026-08-17T13:05:00-07:00

GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-08-13T13:48:32.62830774Z

Analyst Upgrades
Citizens Upgrades Annexon to Market Perform

2026-08-12T03:05:00-07:00

GlobeNewswire
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

2026-08-12T03:00:00-07:00

GlobeNewswire
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

2026-08-10T13:05:00-07:00

GlobeNewswire
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

2026-08-06T05:00:00-07:00

GlobeNewswire
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

2026-07-30T13:01:00-07:00

GlobeNewswire
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance